Compare Novartis AG (NVS) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Starbucks Corp — how do they compare? Novartis AG trades at $152.38 (market cap $295.37B), while Starbucks Corp trades at $106.7 (market cap $121.59B). The key difference: Novartis AG is far larger — about 2.4× Starbucks Corp's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NVS | SBUX | |
|---|---|---|
Market Cap | $295.37B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $108.37 |
52-Week Low | $119.31 | $78.46 |
Enterprise Value | $336.69B | $140.42B |
Dividend Yield | 3.07% | 2.33% |
Volume | — | 7,493,833 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
